Insights On Facility Design
-
Demonstrating ROI For Increased Digital Plant Maturity
4/28/2022
Cytiva has partnered with the independent software company, Biopharm Services (BPS), to model the costs and associated benefits of increasing digital maturity for monoclonal antibody processes in a biopharma plant utilizing single-use technology.
-
Accelerator℠ Vision Platform
3/11/2022
The Pall Accelerator Vision Platform gives you the ability to create virtual replicas of process equipment displayed in your manufacturing facility.
-
Cleanliness Is Next To Godliness In Medicinal Manufacturing
2/23/2022
Cleanrooms in the pharmaceutical, biotech, medical device, and life sciences industries reduce particulate contamination and control environmental parameters including temperature, humidity, and pressure.
-
Never Too Early To Plan For Automation
2/22/2022
Early platform design selections can greatly affect your future automation flexibility and ability to show compliance throughout regulatory reviews.
-
The Impact Of Facility Design On The Safety Of Viral Vectors
2/18/2022
It is critical to vet not just the expertise available at a CDMO, but also the effectiveness of their facility design to reduce risk and meet scale-up needs.
-
In-House Manufacturing: Key To Driving A Diabetes Vaccine?
1/28/2022
Increasing constraints on today’s supply chain from the COVID-19 pandemic mean drug companies must secure strategies that can ensure product delivery in the face of these challenges.
-
Enabling Bioprocess Control With Successful Automation Strategies
12/9/2021
In a recent live event with Bioprocess Online, industry experts at various stages of their automation journey discussed their approach to enhancing quality control and data integrity through automated technologies.
-
Biopharmaceuticals Development And Manufacturing: Wide-Ranging Expertise And Vertically Integrated Service
11/17/2021
The company’s wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art cGMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing.
-
Modular Facilities - The Proven Response For Rapid Biomanufacturing Anywhere
9/28/2021
Select one of the flexible, prefabricated cGMP biomanufacturing environment with a configurable production line that future-proofs capacity expansion, improves operational efficiency and minimizes infrastructure to begin manufacturing faster for a fraction of the cost.
-
Increasing mRNA Capabilities, Capacity
9/20/2021
The growing mRNA vaccine market ― projected to reach $127.3 billion by 2027 ― is fueling high demand for mRNA, which has resulted in a critical need to address mRNA manufacturing bottlenecks.